Direct Long-acting Antibodies: Updating the Language of RSV Prevention to Reflect the Evolution of mAbs

Conclusions:This change will more accurately convey thespecificmode of action of a mAb in infants, and how it could impact the prevention of communicable diseases: this class of mAbs is not an active treatment, but rather will offer direct and rapid protection lasting at least 5 months.

Source: Journal of Preventive Medicine and Hygiene - January 31, 2024 Category: International Medicine & Public Health Authors: Pier-Luigi Lopalco, Susanna Maria Roberta Esposito, Federico Martin ón-Torres , Jacqui Thornton, Todd Wolynn, Giovanni Checcucci Lisi, Kocfa Chung-Delgado, Stephanie Evans, Tapas Mukherjee, Amit Patel, Claire Fellingham, Ben Pounds, Charlotte Harris, Bra Source Type: research